Gain Therapeutics announced that Eurostars and Innosuisse have awarded a grant in the aggregate amount of EUR 1.2M to a consortium led by Gain Therapeutics which includes the Institute for Research in Biomedicine, Newcells Biotech and the University of Helsinki. This grant supports a research project to develop novel small molecule allosteric regulators against Alpha-1 Antitrypsin, AAT, Deficiency, a rare genetic condition that can result in serious lung and liver diseases. "We are pleased that Eurostars and Innosuisse recognize that Gain Therapeutics’ allosteric small molecule regulators provide a new approach to address AAT deficiency-related metabolic diseases. We look forward to advancing our AAT program with this consortium, which combines our unique targeting approach with novel in vitro and in vivo models. This grant validates the capability of our computational discovery platform SEE-Tx to identify previously unknown allosteric binding sites on protein targets in CNS, oncology and now metabolic disease," said Dr. Manolo Bellotto, Chief Strategic Officer and General Manager at Gain Therapeutics.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GANX:
- Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
- Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- Gain Therapeutics presents preclinical data from Gaucher Disease Program
- Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium